Агомелатин, первый мелатонинергический антидепрессант: открытие, характеристики и развитие



страница3/3
Дата13.08.2016
Размер0.5 Mb.
1   2   3
СПИСОК ЛИТЕРАТУРЫ

  1. Sartorius, N. et al. Antidepressant medications and other treatments of depressive disorders: a CINP task force report based on a review of evidence. Int. J. Neuropsychopharmacol. 10, S1-S207 (2007).

  2. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110, 135-370 (2006).

  3. Papakostas, G. I. Tolerability of modern antidepressants. J. Clin. Psychiatry 69, 8-13 (2008).

  4. Eitan, R. & Lerer, B. Neuropharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin. Neurosci. 8, 241-258 (2006).

  5. DeRubeis, R. J., Siegle, G. J. & Hollon, S. D. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nature Rev. Neurosci. 9, 788-796 (2008).

  6. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6, 53-77 (2009).

  7. Mathew, S. J., Manji, H. K. & Charney, D. S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33, 2080-2092 (2008).

  8. Rozas, I. Improving antidepressant drugs: update on recently patented compounds. Expert Opin. Ther. Patents 19, 827-845 (2009).

  9. Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C. & Shelton, R. C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry 62, 1217-1227 (2007).

  10. Montgomery, S. A. et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int. Clin. Psychopharmacol. 22, 323-329 (2007).

  11. Morilak, D. A. & Frazer, A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 7, 193-218 (2007).

  12. Mclntyre, M. & Moral, M. A. Augmentation in treatment-resistant depression. Drugs Future 31, 1069-1081 (2006).

  13. Wong, E. H., Nikam, S. S. & Shahid, M. Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr. Opin. Investig. Drugs 9, 28-36 (2008).

  14. Kehne, J. H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol. Disord. Drug Targets 6, 163-182 (2007).

  15. Ebner, K., Sartori, S. B. & Singewald, N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 154, 1647-1674 (2009).

  16. Kramer, M. S. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385-392 (2004).

  17. Binneman, B. et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165, 617-620 (2008).

  18. Preskorn, S. H. et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective, N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631-637 (2008).

  19. Manji, H. K. et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol. Psychiatry 53, 707-742 (2003).

  20. Pittenger, C. & Duman, R. S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109 (2008).

  21. Souetre, E. et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psych. Res. 28, 263-278 (1989).

  22. Duncan, W. C. Circadian rhythms and the pharmacology of affective illness. Pharmacol. Ther. 71 , 253-312 (1996).

  23. Germain, A. & Kupfer, D. J. Circadian rhythm disturbances in depression. Hum. Psychopharmacol. 23, 571-585 (2008).

  24. Filadelfi, A. M. & Castrucci, A. M. Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates. J. Pineal Res. 20, 175-186 (1996).

  25. Pandi-Perumal, S. R. et al. Melatonin: nature's most versatile biological signal? FEBS J. 273, 2813-2838 (2006).

  26. Arendt, J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev. Reproduction 3, 13-22 (1998).

  27. Cardinali, D. P., Vacas, M. I. & Boyer, E. E. Specific binding of melatonin in bovine brain. Endocrinology 105, 437-441 (1979).

  28. Vanecek, J., Pavlik, A. & lllerova, H. Hypothalamic melatonin receptor sites revealed by autoradiography. Brain Res. 435, 359-362 (1987).

  29. Reppert, S. M., Weaver, D. R. & Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 17, 100-102 (1996).

  30. Morgan, P. J., Barrett, P., Howell, H. E. & Helliwell, R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24, 101-146 (1994).

  31. Macchi, M. M. & Bruce, J. N. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol. 25, 177-195 (2004).

  32. Racagni, G., Riva, M. A. & Popoli, M. The interaction between the internal clock and antidepressant efficacy. Int. Clin. Psychopharmacol. 22, S9-S14 (2007).

  33. Guardiola-Lemaitre, B. in Advances in Pineal Research. (eds Foldes, A. & Reiter, R. J.) 351-363 (John Libbey, London, 1991).

  34. Guardiola-Lemaitre, B. & Delagrange, P. Melatonin analogues: from pharmacology to clinical application. Eur. J. Med. Chem. 30, S643-S651 (1995).

  35. Adam, G. et al. New naphthalenic ligands of melatoninergic receptors J. Pharm. Belg. 47, 374-380 (1992).

  36. Yous, S. et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem. 35, 1484-1485 (1992).

Идентификация агомелатина как высоко потенциального лиганда мелатонинергических рецепторов.

  1. Van Reeth, O. et al. Comparative effects of a melatonin agonist on the circadian system in mice and syrian hamsters. Brain Res. 762, 185-194 (1997).

  2. Ying, S. W. et al. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur. J. Pharmacol. 296, 33-42 (1996).

Подтверждение свойств агомелатина как агониста популяции мелатонинергических рецепторов в супрахиазматическом ядре.

  1. Audinot, V. et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmeidebergs Arch. Pharmacol. 36, 553-561 (2003).

  2. Witt-Enderby, P. A., Bennett, J., Jarzynka, M. J., Firestine, S. & Melan, M. A. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci. 72, 2183-2198 (2003).

  3. Gerdin, M. J. et al. Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 receptors. J. Pharmacol. Exp. Ther. 304, 931-939 (2003).

  4. Gerdin, M. J. et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J. 18, 1646-1656 (2004).

  5. Ying, S. W., Rusak, B. & Mocaer, E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur. J. Pharmacol. 342, 29-37 (1998).

  6. Martinet, L., Guardiola-LemaTtre, B. & Mocaer, E. Entrainment of circadian rhythms by S20098 a melatonin agonist is dose and plasma concentration dependent. Pharmacol. Biochem. Behav. 54, 713-718 (1996).

  7. Redman, J. R., Guardiola-LemaTtre, B., Brown, M., Delagrange, P. & Armstrong, S. M. Dose-dependent effects of, S20098, a melatonin agonist on direction of re-entrainment of rat circadian rhythms. Psychopharmacology 11 8, 385-390 (1995).

  8. Armstrong, S. M., McNulty, O. M., Guardiola-LemaTtre, B. & Redman, J. R. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome. Pharmacol. Biochem. Behav. 46, 45-49 (1993).

In vivo исследование, подтверждающее, что агомелатин эффективно корректирует циркадианные ритмы.

  1. Wirz-Justice, A. et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol. Med. 35, 939-944 (2005).

  2. Emens, J., Lewy, A., Kinzie, J. M., Arntz, D. & Rough, J. Circadian misalignment in major depressive disorder. Psychiatry Res. 168, 259-261 (2009).

  3. Van Reeth, O. et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to an environmental stimulus. Am. J. Physiol. 280, 1582-1591 (2001).

  4. Koster-van Hoffen, G. C. et al. Effects of a novel melatonin analog on circadian rhythms of body temperature and activity in young, middle-aged, and old rats. Neurobiol. Aging 14, 565-569 (1993).

  5. Grassi-Zucconi, G., Semprevivo, M., Mocaer, E., Kristensson, K. & Bentivoglio, M. Melatonin and its new agonist, S20098 restore synchronised sleep fragmented by experimental trypanosome infection in the rat. Brain Research Bull. 39, 63-68 (1996).

  6. Van Reeth, O., Olivares, E., Turek, F. W., Granjon, L. & Mocaer, E. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 9, 1901-1905 (1998).

  7. Wirz-Justice, A. et al. Early evening melatonin and, S20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol. 272, R1178-R1188 (1997).

  8. Redman, J. R. & Francis, A. J. Entrainment of rat circadian rhythms by the melatonin agonist, S20098 requires intact suprachiasmatic nuclei but not the pineal. J. Biol. Rhythms 13, 39-51 (1998).

  9. Pitrosky, B., Kirsch, R., Malan, A., Mocaer, E. & Pevet, P. Organization of rat circadian rhythms during daily infusion of melatonin or, S20098, a melatonin agonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277, 812-828 (1999).

  10. Jockers, R., Maurice, P., Boutin, J. A. & Delagrange, P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br. J. Pharmacol. 154, 1182-1195 (2008).

  11. Cajochen, C., Krauchi, K., Mori, D., Graw, P. & Wirz-Justice, A. Melatonin and S20098 increase REM and wake-up propensity without modifying NREM sleep homeostasis. Am. J. Physiol. Regul. Integrative Comp. Physiol. 272, R1189-R1196 (1997).

  12. Krauchi, K., Cajochen, C., Mori, D., Graw, P. & Wirz-Justice, A. Early evening melatonin and S20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol. Regul. Integrative Comp. Physiol. 272, R1178-R1188 (1997).

Исследование, подтверждающее, что у здоровых добровольцев при вечернем назначении агомелатин достоверно и стойко влияет на циркадианные ритмы в течение 24 часов.

  1. Burns, C. M. et al. Regulation of serotonin2C receptor, G-protein coupling by RNA editing. Nature 387, 303-308 (1997).

  2. Millan, M. J., Marin, P., Bockaert, J. & la Cour, C. M. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 29, 454-464 (2008).

  3. Aloyo, V. J., Berg, K. A., Spampinato, U., Clarke, W. P. & Harvey, J. A. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol. Ther. 121 , 160-173 (2009).

  4. Chanrion, B. et al. lnverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol. Pharmacol. 73, 748-757 (2008).

  5. Berg, K. A. et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54, 94-104 (1998).

  6. Millan, M. J. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306, 954-964 (2003).

Подтверждение, что агомелатин действует как антагонист клонированных, человеческих и нативных 5-HT2C рецепторов головного мозга.

  1. Giorgetti, M. & Tecott, L. H. Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 488, 1-9 (2004).

  2. Millan, M. J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60, 441-460 (2005).

  3. Kennaway, D. J. & Moyer, R. W. Serotonin 5-HT2C agonists mimic the effect of light pulses on circadian rhythms. Brain Res. 806, 257-270 (1998).

  4. Barassin, S. et al. Circadian tryptophan hydroxylase levels and serotonin release in the suprachiasmatic nucleus of the rat. Eur. J. Neurosci. 15, 833-840 (2002).

  5. Varcoe, T. J. & Kennaway, D. J. Activation of 5-HT2C receptors acutely induces Perl gene expression in the rat SCN in vitro. Brain Res. 1209, 19-28 (2008).

  6. Cuesta, M., Clesse, D., Pevet, P. & Challet, E. New light on the serotonergic paradox in the rat circadian system. J. Neurochem. 110, 231-243 (2009).

  7. Gannon, R. L. & Millan, M. J. Serotonin1A autoreceptor activation by, S15535 enhances circadian activity rhythms in hamsters: evaluation of potential interactions with serotonin2A and serotonin2C receptors. Neuroscience 137, 287-299 (2006).

  8. Stahl, S. M., Grady, M. M., Moret, C. & Briley, M. SNRls: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10, 732-747 (2005).

  9. Kasper, S. & Hamon, M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry 10, 117-126 (2009).

  10. Linnik, l. V. et al. The novel antidepressant, agomelatine, blocks cerebral 5-HT2C receptors in vivo: a phMRl challenge study in rats. Eur. Neuropsychopharmacol. 19, S259 (2009).

  11. Papp, M., Gruca, P., Boyer, P. A. & Mocaer, E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28, 694-703 (2003).

Модель ангедонии - первое доказательство, что агомелатин обладает отчетливыми антидепрессивными свойствами, которые реализуются за счет механизма взаимодействия мелатонинергических и 5-HT2C рецепторов.

  1. Bourin, M., Mocaer, E. & Porsolt, R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci. 29, 126-133 (2004).

  2. Alex, K. D. & Pehek, E. A. Pharmacological mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 11 3, 296-320 (2007).

  3. Banasr, M., Hery, M., Mocaer, E. & Daszuta, A. Agomelatine, a new antidepressant drug, increases cell proliferation, maturation and survival of newly generated granule cells in adult hippocampus. Biol. Psychiatry 59, 1087-1096 (2006).

Длительная терапия агомелатином усиливает клеточную пролиферацию и нейрогенез в гиппокампе - механизм, свойственный антидепрессантам других классов и участвующий в улучшении настроения.

  1. Soumier, A. et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34, 2390-2403 (2009).

  2. Barden, N. et al. Antidepressant action of agomelatine (S20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 908-916 (2005).

  3. Norman, T. R., Cranston, l. & lrons, J. Effect of the novel antidepressant agomelatine in the olfactory bulbectomised rat. Int. J. Neuropsychopharmacol. 7, S461 (2004).

  4. Dekeyne, A. et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology 199, 549-568 (2008).

  5. Bertaina-Anglade, V., la Rochelle, C. D., Boyer, P. A. & Mocaer, E. Antidepressant-like effects of agomelatine (S20098) in the learned helplessness model. Behav. Pharmacol. 17, 703-713 (2006).

  6. Corbach, S., Schmelting, B., Fuchs, E. & Mocaer, E. Comparison of agomelatine and melatonin for effects in chronically stressed tree shrews, an animal model of depression. Eur. Neuropsychopharmacol. 17, S364 (2007).

  7. Corbach-Sohle, S. et al. Effects of agomelatine and S32006, a selective 5-HT2C receptor antagonist, in chronically-stressed tree shrews. Eur. Neuropsychopharmacol. 18, S348 (2008).

  8. Overstreet, D. H., Pucilowski, O., Rettori, M. C., Delagrange, P. & Guardiola-Lemaitre, B. Effects of melatonin receptor ligands on swim test immobility. Neuroreport 29, 249-253 (1998).

  9. Weil, Z. M., Hotchkiss, A. K., Gatien, M. L., Pieke-Dahl, S. & Nelson, R. J. Melatonin receptor (MT1) knockout mice display depression-like behaviours and deficits in sensorimotor gating. Brain Res. Bull. 68, 425-429 (2006).

  10. Olie, J. P. & Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 10, 661-673 (2007).

  11. Descamps, A. et al. lnfluence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 205, 93-106 (2009).

  12. Quera-Salva, M. A. et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J. Neuropsychopharmacol. 10, 691-696 (2007).

  13. Wilson, S. & Argyropoulos, S. Antidepressants and sleep: a qualitative review of the literature. Drugs 65, 927-947 (2005).

  14. Leproult, R., Van Onderbergen, A., L'Hermite-Baleriaux, M., Van Cauter, E. & Copinschi, G. Phase-shifts of 24h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. 63, 298-304 (2005).

  15. Kennedy, S. J. & Rizvi, S. J. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 24, 479-499 (2010).

  16. Loo, H., Hale, A. & D'haenen, H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 17, 239-247 (2002).

Основные исследования, подтверждающие клиническую ценность агомелатина в терапии большой депрессии.

  1. Leuchter, A. F. et al. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology 177, 15-22 (2004).

  2. Berk, M. & Dodd, S. Antidepressants and the placebo response. Hum. Psychopharmacol. Clin. Exp. 20, 305-307 (2005).

  3. Kennedy, S. H. & Emsley, R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 16, 93-100 (2006).

  4. Lemoine, P., Guilleminault, C. & Alvarez, E. lmprovement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double blind comparison with venlafaxine. J. Clin. Psychiatry 68, 1723-1732 (2007).

  5. Kasper, S. et al. Efficacy of the novel antidepressant agomelatine on the circadian and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 71 , 109-120 (2010).

  6. Kennedy, S. H., Rizvi, S., Fulton, K. & Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol. 28, 329-333 (2008).

  7. Srinivasan, V. et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 165, 201-214 (2009).

  8. Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F. & Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 70, 1128-1137 (2009).

Антидепрессивный эффект агомелатина стойко сохраняется в течение 6 месяцев терапии и определяет его эффективность в профилактике рецидивов.

  1. Goodwin, G., Rouillon, F. & Emsley, R. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months. Eur. Neuropsychopharmacol. 18, S338 (2009).

  2. Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M. & Hindmarch, l. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 19, 271-280 (2004).

Подтверждение того, что резкоая остановка терапия агомелатином при большой депрессии не приводит к развитию симптомов отмены в отличие от СИОЗС пароксетина.

  1. Baldwin, D. S., Montgomery, S. A., Nil, R. & Lader, M. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 10, 73-84 (2007).

  2. Aronne, L. J. & Segal, K. R. Weight gain in the treatment of mood disorders. J. Clin. Psychiatry. 64 (Suppl. 8), 22-29 (2003).

  3. Serretti, A. & Chiesa, A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 29, 259-266 (2009).

  4. Drago, F. & Busa, L. Acute low doses of melatonin restore full sexual activity in impotent male rats. Brain Res. 878, 98-104 (2000).

  5. Brotto, L. A., Gorzalka, B. B. & LaMarre, A. K. Melatonin protects against the effects of chronic stress on sexual behaviour in male rats. Neuroreport 12, 3465-3469 (2001).

  6. Hull, E. M., Muschamp, J. W. & Sato, S. Dopamine and serotonin influences on male sexual behaviour. Physiol. Behav. 83, 291-307 (2004).

  7. Montejo, A. et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol. 24, 111-120 (2009).

  8. Musazzi, L. et al. Stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 5, e8566 (2010).

  9. Walker, M. P. & Stickgold, R. Sleep, memory, and plasticity. Annu. Rev. Psychol. 57, 139-166 (2006).

  10. Bruel-Jungerman, E., Rampon, C. & Laroche, S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev. Neurosci. 18, 93-114 (2007).

  11. Eckel-Mahan, K. L. & Storm, D. R. Circadian rhythms and memory: not so simple as cogs and gears. EMBO Rep. 10, 584-591 (2009).

  12. Austin, M. P., Mitchell, P. & Goodwin, G. M. Cognitive deficits in depression: possible implications for functional neuropathology. Br. J. Psychiatry 178, 200-206 (2001).

  13. Conboy, L. et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int. J. Neuropsychopharmacol. 12, 329-341 (2009).

  14. Castro-Costa, E. et al. Prevalence of depressive symptoms and syndromes in later life in ten European countries, the SHARE study. Br. J. Psychiatry 191, 393-401 (2007).

  15. Magnusson, A. & Partonen, T. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. CNS Spectr. 10, 625-634 (2005).

  16. Pjrek, E. et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 190, 575-579 (2007).

  17. Schoevers, R. A., Van, H. L., Koppelmans, V., Kool, S. & Dekker, J. J. Managing the patient with co-morbid depression and an anxiety disorder. Drugs 68, 1621-1634 (2008).

  18. Tuma, J., Strubbe, J. H., Mocaer, E. & Koolhaas, J. M. Anxiolytic-like action of the antidepressant agomelatine (S20098) after a social defeat requires the integrity of the SCN. Eur. Neuropsychopharmacol. 15, 545-555 (2005).

  19. Heisler, L. K., Zhou, L., Bajwa, P., Hsu, J. & Tecott, L. H. Serotonin 5-HT2C receptors regulate anxiety-like behaviour. Genes Brain Behav. 6, 491-496 (2007).

  20. Millan, M. J., Brocco, M., Gobert, A. & Dekeyne, A. Anxiolytic properties of agomelatine, and antidepressant with melatonergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 177, 448-458 (2005).

  21. Papp, M., Litwa, E., Gruca, P. & Mocaer, E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 17, 9-18 (2006).

  22. Stein, D. J., Ahokas, A. A. & de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28, 561-566 (2008).

Первое подтверждение клинической эффективности агомелатина в терапии генерализованного тревожного расстройства.

  1. Boivin, D. B. lnfluence of sleep-wake and circadian rhythm disturbance in psychiatric disorders. J. Psychiatry Neurosci. 25, 446-458 (2000).

  2. Srinivasan, V. et al. Melatonin in mood disorders. World J. Biol. Psychiatry 7, 138-151 (2006).

  3. Luo, A. H. & Aston-Jones, G. Circuit projection from suprachiasmatic nucleus to ventral tegmental area: a novel circadian output pathway. Eur. J. Neurosci. 29, 748-760 (2009).









Поделитесь с Вашими друзьями:
1   2   3


База данных защищена авторским правом ©uverenniy.ru 2019
обратиться к администрации

    Главная страница